Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) major shareholder Medpace Investors, Llc acquired 57,426 shares of Medpace stock in a transaction dated Thursday, September 22nd. The shares were acquired at an average price of $154.59 per share, with a total value of $8,877,485.34. Following the completion of the transaction, the insider now owns 6,483,019 shares of the company's stock, valued at approximately $1,002,209,907.21. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Medpace Investors, Llc also recently made the following trade(s):
Get
Medpace alerts:
- On Monday, September 19th, Medpace Investors, Llc acquired 94,119 shares of Medpace stock. The shares were acquired at an average price of $153.48 per share, with a total value of $14,445,384.12.
- On Tuesday, September 13th, Medpace Investors, Llc bought 62,516 shares of Medpace stock. The stock was purchased at an average price of $157.12 per share, with a total value of $9,822,513.92.
Medpace Stock Performance
Shares of NASDAQ MEDP traded down $9.45 during trading on Friday, hitting $145.38. The company had a trading volume of 624,044 shares, compared to its average volume of 345,257. The company has a market cap of $4.51 billion, a P/E ratio of 24.82 and a beta of 1.47. Medpace Holdings, Inc. has a 52 week low of $126.94 and a 52 week high of $231.00. The business's 50-day moving average is $161.45 and its 200 day moving average is $152.75.
Medpace (NASDAQ:MEDP – Get Rating) last posted its quarterly earnings results on Monday, July 25th. The company reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.12. The company had revenue of $351.21 million for the quarter, compared to analysts' expectations of $344.01 million. Medpace had a return on equity of 30.56% and a net
margin of 16.27%. The firm's revenue was up 26.2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.06 earnings per share. On average, research analysts expect that Medpace Holdings, Inc. will post 6.16 EPS for the current year.
Institutional Inflows and Outflows
Several institutional investors have recently modified their holdings of the stock. Wasatch Advisors Inc. raised its stake in Medpace by 12.1% during the 1st quarter. Wasatch Advisors Inc. now owns 2,728,392 shares of the company's stock valued at $446,338,000 after purchasing an additional 294,103 shares during the period. Boston Trust Walden Corp raised its stake in Medpace by 38.2% during the 1st quarter. Boston Trust Walden Corp now owns 674,994 shares of the company's stock valued at $110,423,000 after purchasing an additional 186,518 shares during the period. Riverbridge Partners LLC raised its stake in Medpace by 44.1% during the 2nd quarter. Riverbridge Partners LLC now owns 481,404 shares of the company's stock valued at $72,052,000 after purchasing an additional 147,225 shares during the period. Loomis Sayles & Co. L P raised its stake in Medpace by 149.5% during the 4th quarter. Loomis Sayles & Co. L P now owns 233,242 shares of the company's stock valued at $50,763,000 after purchasing an additional 139,767 shares during the period. Finally, Echo Street Capital Management LLC raised its stake in Medpace by 18.4% during the 1st quarter. Echo Street Capital Management LLC now owns 695,336 shares of the company's stock valued at $113,750,000 after purchasing an additional 108,133 shares during the period. Institutional investors own 83.97% of the company's stock.
Wall Street Analysts Forecast Growth
A number of research firms have weighed in on MEDP. StockNews.com downgraded Medpace from a "buy" rating to a "hold" rating in a research report on Thursday, September 8th. UBS Group began coverage on Medpace in a research report on Wednesday, September 7th. They issued a "sell" rating and a $142.00 target price for the company.
About Medpace
(Get Rating)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Stories
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- Why Does Tesla Stock Remain Resilient?
- Will Crowdstrike Get A Boost From Increased EPS Guidance?
- Is Costco's Post-Earnings Price Weakness A Good Time To Buy?
- 2 Semiconductor Stocks To Watch For Reversals
- Are Layoffs At A Small-Cap Tech A Bellwether For Housing Stocks?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.
